Richard Butt, Apollo Therapeutics

"We have to be sure that the mechanism we're targeting can be followed through to a disease, and a clinical & medical need. It doesn't matter if the science is really cool if there's ultimately nowhere to translate it to, so it's really important that we stay on top of emerging trends." Academia and industry have increasingly been joining forces to drive innovation in drug discovery, but they remain separate worlds in many ways. We spoke to Richard Butt, CEO of Apollo Therapeutics, who have a unique approach to industry-academia collaboration, about: 🎓 The differences between the two sectors 🎓 Why commercial analysis is important, but shouldn't be overdone 🎓 What he looks for in a spin-out technology 🎓 The upward trends in UK biotech Enjoy!